slow responder to glp 1 Why GLP-1 Non-Responders Need Earlier Anti-Obesity Medication Intervention GlobalRPH Understanding GLP-1 Slow Responders in

Its actions include: Muscle Growth: Activates protein synthesis through the PI3K/Akt/mTOR pathway, leading to stronger and denser muscle fibers

Together, GLP-1R, GIPR, and GCGR agonists are expected to see more clinical trial evidence to prove their efficacy and safety in treating obese patients

It is well established that patients with diabetes demonstrate higher susceptibility to pancreatic cancer and pancreatitis compared to non-diabetic individuals, and theoretically, sustained GLP-1 receptor activation induced by GLP-1RA therapy may potentially elevate pancreatic cancer risk [8]

Pancharuniti N, Lewis CA, Sauberlich HE, Perkins LL, Go RCP, Alvarez JO, Macaluso M, Acton RT, Copeland RB, Cousins AL, Gore TB, Cornwell PE, and Roseman JM (1994)